Please refer the enclosed intimation letter
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare's board approved multiple items at its May 7, 2026 meeting. Key outcomes include recommending a final dividend of Rs. 7 per share for FY 2025-26 (total dividend of Rs. 9.33 per share post-bonus), switching statutory auditors from M S K A & Associates LLP to Price Waterhouse Chartered Accountants LLP for a 5-year term, and re-appointing CEO Rahul Franklin Guha for another 5 years from May 2027. Two Non-Executive Non-Independent Directors — Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah — resigned citing pre-occupation and other commitments, with effect from close of business on May 7, 2026. Both stated no material reasons for resignation. Two new Additional Directors, Uday Patel Kadam and Gaurav Verma (both linked to API Holdings/PharmEasy), were appointed from May 8, 2026. The board also approved investing up to Rs. 5.5 crore in Think Health Diagnostics Private Limited (a wholly owned subsidiary, related party transaction at arm's length) and proposed altering the Memorandum of Association to align with the Companies Act 2013 and broaden the objects clause to cover a wider healthcare and diagnostics ecosystem.
Two board departures in a single meeting reduce board independence and may raise governance concerns. The new directors from API Holdings deepen the parent group's control. The related party investment in Think Health and MOA amendment signal expansion into broader healthcare services. The dividend recommendation is positive for income-seeking investors.